Overview of Yellow Fever Vaccine through UNICEF

Vaccine Industry Consultation – 15/16 November 2016
Overview

• Background
• Supply
• Demand
• Next tender
• Key message (“takeaways”)
Background

Issue

- YF is endemic and non-eradicable disease and 40 countries in Africa and Latin America are at highest risk: Need to establish high levels of immunity
  - Coverage in countries recommended to introduce YFV in routine: 68% with targeted >80% by district
  - In Africa, 5 countries still need to introduce YFV into their routine programmes and 12 countries conduct mass campaigns
- Beg 2016 – YF outbreaks in Angola, DRC and Uganda resulted in Emergency Stockpile depletion
  - Two linked urban YF outbreaks (Luanda and Kinshasa), with wider international exportation from Angola
  - 29.1 mio.ds supplied for OR in 2016 to date

Response

WHO’s new control strategy: Eliminate Yellow fever Epidemics (EYE)

- Implement and strengthen coverage rates of childhood vaccination, 9 months of age
- Conduct preventive mass vaccination campaigns, to rapidly increase immunity
- Maintain a stockpile for reactive campaigns, to immediate outbreaks response
Background

What have we done?

YF partners agreement in allocation of available vaccine

1. Temporary **rereallocation** of YFV from routine programmes and preventative campaigns to increase vaccine availability to respond to outbreaks, even using **fractional dose** (1/5th)
2. When total vaccine availability with suppliers exceeds 6 mio.ds, countries will receive vaccine equivalent to **2-month** routine supply
3. Preventative campaigns **on hold**; approved supply for migrants
Supply

Source: UNICEF Supply Division
Demand (2017 – 2024)

**Routine:** Increase routine coverage to >80% (by district) in endemic countries
New countries to address UNICEF for YFV to their routine programmes

**Supplementary:**
- **Stockpile:** Secure Revolving Emergency Stockpile at 6 mio.ds
- **Migrants:** Secure access to migrants to avoid cross-border transmission
- **Campaigns:** More mass campaigns (main demand driver)
Demand (2017 – 2024)

Projected demand through UNICEF
Next tender

1. Issue a tender during **Q1 2017** with the aim of awarding by 30 June 2017 for supply starting in January 2018

2. Tender objectives:
   - **Vaccine security** with sufficient availability to meet demand for routine, campaigns and Emergency Stockpile; in optimal YFV presentation
   - Continue focus on offering **affordable prices**
   - Move the market to a healthier state

3. Request for Proposal (RFP); **3 years** (2018 – 2020)

4. **UNICEF** forecasted demand will be split between routine, campaigns and Emergency Stockpile

5. **Revolving Emergency Stockpile**: maintain a stock of 6 mio.ds at any time
   - Stockpile **immediately replenished** after its use in an outbreak - UNICEF SD works closely with suppliers to ensure 6 mio.ds always in stock
   - Suppliers rotate the stocks between the Stockpile and preventive campaigns to ensure **no wastage** due to expiration of vaccine
Healthy Market Framework

• Demand still surpasses supply, but there is a certain degree of healthiness in the market...
  • 4 WHO PQ suppliers, 4 countries, all functional
  • Different presentations available (YFV-5, -10 and -20)
  • Increased supply (although so does the demand!)
  • Some product innovation plans (live-attenuated YF virus on cell culture instead of on SPF embryonated eggs)

Developed jointly by BMGF, Gavi and UNICEF
Key messages ("takeaways")

1) Increasing demand expecting supply will follow

2) Revolving Emergency Stockpile: maintain a stock of 6 mio.ds at any time

3) UNICEF tender in Q1 2017 for supply 2018+